ClinicalTrials.gg
Active, not recruitingNCT05761977DRIVEUpdated Oct 15, 2026

Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer

An observational study in Small-cell Lung Cancer and Extensive-stage Small-cell Lung Cancer, sponsored by Hellenic Cooperative Oncology Group. Active, not recruiting at 1 site in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Hellenic Cooperative Oncology Group · Observational

How we know · 2 judgments

Updated Oct 15, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Small Cell Lung Carcinoma with a site in Greece — 10 open to participants now, 22 under way, 16 of them phase 3. Small Cell Lung Carcinoma · Greece.

Started
2021
with 3 others
Observational
3 of 36
1 open now
Primary completion
2026-01
later than 3 of 21 live
Registered
20th of 36
by date
Lead sponsor
2 of 36
Hellenic Cooperative Oncology Group

Among the 36 studies in Small Cell Lung Carcinoma with a site in Greece, this one is one of 4 that started in 2021, is one of 3 observational ones, reaches primary completion later than 3 of the 21 other live ones, and was the 20th registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

10 of the 36 studies in Small Cell Lung Carcinoma with a site in Greece are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Small Cell Lung Carcinoma with a site in Greece, or all of them as a file.
02

Study summary

This is a non-interventional, multicenter, prospective observational study and registry of standard clinical practice in patients with Extensive Stage-Small Cell Lung Cancer (ES-SCLC) receiving 1st line treatment with Durvalumab in combination with standard chemotherapy (cisplatin or carboplatin + etoposide) in the approved indication, which will be carried out in Greece. In this study data will be collected prospectively based on real-world clinical practice. A prospective cohort of atients from centers of the Hellenic Cooperative Oncology Group (HeCOG) will be included. The study will be conducted in hospitals and by physicians specialized in lung cancer from different geographical areas of Greece.

Read the detailed description

In this observational prospective study, no changes to current therapeutic practice will be required and all aspects of treatment and clinical management of patients will be in compliance with the local clinical practice and will be left to the discretion of the participating physicians. Patients will be treated in accordance with the study medicine's local prescribing information and standard clinical practice as to the frequency of visits and types of evaluations carried out. The frequency of follow-up visits is set on the basis of standard practice; however, the study-related data will be collected during integration and during the routine clinical visits that will take place after the start of treatment. No visits or measurement/evaluation will be mandatory by the protocol and data collection at the predetermined time-points will be carried out only if the patient visits the center.

Patients will be enrolled during a 12-month recruitment period from HeCOG-participating public and private centers/clinics in Greece with specialization in lung cancer. As part of this study, participating physicians will be asked to follow up each patient for an additional 12 months of treatment at most after last subject is included, or until death, withdrawal of consent, discontinuation of treatment or initiation of new antineoplastic therapy, until completion of the study, or doctor's decision, whichever appears first. Therefore, the maximum period of prospective observation of the study will be 24 months (2 years) from the last patient enrolled in the study. This study will be conducted in accordance with the Guidelines for Good Pharmacoepidemiological Practice, the European General Data Protection Regulation (GDPR) and the applicable regulatory requirements.

03

Conditions studied

  • Small-cell Lung Cancer
  • Extensive-stage Small-cell Lung Cancer

Keywords

  • observational study
  • small- cell lung cancer
  • extensive-stage small-cell lung cancer
  • first line treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with Small- Cell Lung Cancer candidates for 1st- line immunotherapy plus platinum based chemotherapy (cisplatin or carboplatin plus etoposide) currently with active disease.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients, regardless of race (residents in Greece), no younger than 18 years old at the initiation of treatment.
  • Patients with or cytologically confirmed diagnosis of extensive Small Cell Lung Cancer (SCLC)
  • Patients who have not received prior systemic treatment for SCLC (chemotherapy or immunotherapy)
  • Patients for whom the decision to administer treatment with Durvalumab+chemotherapy has already been taken before their inclusion in the study and is clearly separated from the decision of the physician for the patient's participation in the current study.
  • Patients who have provided informed signed consent to participate in the study and to collect and analyze medical data related to the objectives of this study.

Exclusion criteria

Exclusion Criteria:

  • Patients with current diagnosis of primary cancer other than SCLC who require systemic or other treatment.
  • Patients who have previously received chemotherapy or immunotherapy for SCLC
  • Patients who are currently receiving or are expected to receive treatment with an drug/medical device/intervention or who have received an investigational medicinal product within 1 month or 5 years half-life of the research agent (whichever is longer) before their initiation in this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patient with extensive small-cell lung cancer

    extensive small-cell lung cancer

This study also gives DurvalumabStudies of DurvalumabDurvalumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Overall survival rates (OS)

    The primary objective of the study is to estimate the overall survival rates (OS) at 6,12 and 24 months for patients with extensive small-cell lung cancer treated with Durvalumab in combination with standard 1st-line chemotherapy with platinum-etoposide(cisplatin or carboplatin).

    Time frame: up to 24 months

Secondary outcomes

  1. Progression free survival (PFS)

    Evaluation of PFS from investigator

    Time frame: in 6, 12 and up to 24 months

  2. Overall response rate (ORR)

    Time frame: in 6 and up to 12 months

  3. Disease Control Rate

    Time frame: in 6 and up to 12 months

  4. time to reach a response (TTR)

    Time frame: up to 12 months

  5. duration of the response (DoR)

    Time frame: up to 12 months

  6. Assessment of patients characteristics with overall survival 12 months

    Time frame: up to 12 months

  7. Assessment of patients characteristics with overall survival 24 months

    Time frame: up to 24 months

  8. time under treatment (ToT)

    Time frame: up tp 24 months

  9. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 with standard of care 1st line treatment

    Time frame: From date of Informed Consent signatory and every 3 weeks, up to 24 months

  10. Quality of life EQ-5D

    Time frame: From date of Informed Consent signatory and every 2 months, up to 24 months

  11. number of participants using health resources in daily clinical practice

    Time frame: From date of Informed Consent signatory and every 3 weeks, up to 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Jan 2026, 57 months.

Of 62 observational studies under Small Cell Lung Carcinoma, half reached primary completion within 77 months of starting (the median), counting those still running; a quarter within 47. This study's 57 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Apr 2023 → Jan 2026 and completion Apr 2024 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2023
First posted
Mar 9, 2023
StartActual
Mar 31, 2021
Primary completionActual
Jan 15, 2026was Apr 2023
CompletionEst.
Jan 2027was Apr 2024
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Active, not recruiting
changed Oct 15, 2026
Sites
1 site added, 1 site removed
Show site
  • Metropolitan Hospital · Neo Faliro, Greece
Show 1 removed
  • Metropolitan Hospital · Néo Fáliro, Greece
Oct 15, 2026
Primary completion
Apr 2023→Jan 15, 2026 (actual)
Oct 15, 2026
Study completion
Apr 2024→Jan 2027
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Status unknown→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • Metropolitan Hospital · Neo Faliro, Greece
    Show 1 removed
    • Metropolitan Hospital · Néo Fáliro, Greece
    Primary completion Apr 2023→Jan 15, 2026 (now actual)
    Study completion Apr 2024→Jan 2027
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05761977
Lead sponsor
Hellenic Cooperative Oncology Group
Responsible party
Sponsor
First posted
Mar 9, 2023
Start date
Mar 31, 2021
Primary completion
Jan 15, 2026
Completion
Jan 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Helena Linardou, MD
principal investigator · Metropolitan Hospital of Athens

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion